aBLA Filing Intelligence & Biosimilar Opportunity

NexoBrid

Anacaulase-Bcdb

Dermatologic

Topical Gel

Approval Date

28-Dec-22

Data Exclusivity Expiry

28-Dec-26

Market Exclusivity Expiry

28-Dec-34

Commercial snapshot

Market performance & projections

Revenue ($M)

CAGR (%)

0.4453

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

2027

2028

2029

2030

2031

2032

Molecule profile

Details & specifications

Molecule

Anacaulase-Bcdb

Innovator

VERICEL CORPORATION

Dosage Form

Topical Gel

Strength

0.088

Therapeutic Category

Dermatologic

Usage

To remove eschar in adults with deep partial thickness or full thickness thermal burns

Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.